Tags

Type your tag names separated by a space and hit enter

Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.
Breast Cancer Res Treat. 2011 Feb; 126(1):149-55.BC

Abstract

Aspirin and other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit aromatase activity and thus could selectively lower incidence of hormone receptor positive tumors. We assessed whether the association of aspirin and other NSAIDs with postmenopausal breast cancer risk differs by estrogen and progesterone receptor (ER and PR) status of the tumor. A population-based cohort of 26,580 postmenopausal women was linked to a SEER Cancer Registry to identify incident breast cancers. Regular use of aspirin and other NSAIDs was reported on a self-administered questionnaire mailed in 1992. Cox proportional hazards models were used to estimate multivariate relative risks (RRs) and 95% confidence intervals (CIs) of breast cancer incidence overall and by ER and PR status, adjusting for multiple breast cancer risk factors. Through 2005, 1,581 incident breast cancer cases were observed. Compared to aspirin never users, women who regularly consumed aspirin had a lower risk of breast cancer (RR = 0.80; 95% CI: 0.71-0.90), and there was evidence for lower risk with increasing frequency of use (RR = 0.71 for aspirin use 6 or more times/week vs. never use; P trend = 0.00001). Inverse associations for regular aspirin use were observed for ER+ (RR = 0.77; 95% CI 0.67-0.89), ER- (RR = 0.78; 95% CI 0.56-1.08), PR+ (RR = 0.79; 95% CI 0.68-0.92), and PR- (RR = 0.73; 95% CI 0.56-0.95) breast cancers. In contrast, use of other NSAIDs was not associated with breast cancer incidence overall (RR = 0.95, 95% CI: 0.85-1.07), or by ER or PR status. Aspirin, but not other NSAID use, was associated with about 20% lower risk of postmenopausal breast cancer and did not vary by ER or PR status of the tumor, suggesting that the hypothesized protective effects of aspirin may either be through cellular pathways independent of estrogen or progesterone signaling, or on tumor microenvironment.

Authors+Show Affiliations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

20669045

Citation

Bardia, Aditya, et al. "Effect of Aspirin and Other NSAIDs On Postmenopausal Breast Cancer Incidence By Hormone Receptor Status: Results From a Prospective Cohort Study." Breast Cancer Research and Treatment, vol. 126, no. 1, 2011, pp. 149-55.
Bardia A, Olson JE, Vachon CM, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011;126(1):149-55.
Bardia, A., Olson, J. E., Vachon, C. M., Lazovich, D., Vierkant, R. A., Wang, A. H., Limburg, P. J., Anderson, K. E., & Cerhan, J. R. (2011). Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Research and Treatment, 126(1), 149-55. https://doi.org/10.1007/s10549-010-1074-x
Bardia A, et al. Effect of Aspirin and Other NSAIDs On Postmenopausal Breast Cancer Incidence By Hormone Receptor Status: Results From a Prospective Cohort Study. Breast Cancer Res Treat. 2011;126(1):149-55. PubMed PMID: 20669045.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. AU - Bardia,Aditya, AU - Olson,Janet E, AU - Vachon,Celine M, AU - Lazovich,Deann, AU - Vierkant,Robert A, AU - Wang,Alice H, AU - Limburg,Paul J, AU - Anderson,Kristin E, AU - Cerhan,James R, Y1 - 2010/07/29/ PY - 2010/07/14/received PY - 2010/07/17/accepted PY - 2010/7/30/entrez PY - 2010/7/30/pubmed PY - 2011/5/6/medline SP - 149 EP - 55 JF - Breast cancer research and treatment JO - Breast Cancer Res. Treat. VL - 126 IS - 1 N2 - Aspirin and other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit aromatase activity and thus could selectively lower incidence of hormone receptor positive tumors. We assessed whether the association of aspirin and other NSAIDs with postmenopausal breast cancer risk differs by estrogen and progesterone receptor (ER and PR) status of the tumor. A population-based cohort of 26,580 postmenopausal women was linked to a SEER Cancer Registry to identify incident breast cancers. Regular use of aspirin and other NSAIDs was reported on a self-administered questionnaire mailed in 1992. Cox proportional hazards models were used to estimate multivariate relative risks (RRs) and 95% confidence intervals (CIs) of breast cancer incidence overall and by ER and PR status, adjusting for multiple breast cancer risk factors. Through 2005, 1,581 incident breast cancer cases were observed. Compared to aspirin never users, women who regularly consumed aspirin had a lower risk of breast cancer (RR = 0.80; 95% CI: 0.71-0.90), and there was evidence for lower risk with increasing frequency of use (RR = 0.71 for aspirin use 6 or more times/week vs. never use; P trend = 0.00001). Inverse associations for regular aspirin use were observed for ER+ (RR = 0.77; 95% CI 0.67-0.89), ER- (RR = 0.78; 95% CI 0.56-1.08), PR+ (RR = 0.79; 95% CI 0.68-0.92), and PR- (RR = 0.73; 95% CI 0.56-0.95) breast cancers. In contrast, use of other NSAIDs was not associated with breast cancer incidence overall (RR = 0.95, 95% CI: 0.85-1.07), or by ER or PR status. Aspirin, but not other NSAID use, was associated with about 20% lower risk of postmenopausal breast cancer and did not vary by ER or PR status of the tumor, suggesting that the hypothesized protective effects of aspirin may either be through cellular pathways independent of estrogen or progesterone signaling, or on tumor microenvironment. SN - 1573-7217 UR - https://www.unboundmedicine.com/medline/citation/20669045/Effect_of_aspirin_and_other_NSAIDs_on_postmenopausal_breast_cancer_incidence_by_hormone_receptor_status:_results_from_a_prospective_cohort_study_ L2 - https://doi.org/10.1007/s10549-010-1074-x DB - PRIME DP - Unbound Medicine ER -